Phase 3 clinical trial for OTO-313 in tinnitus

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 18 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Nov 2022 According to an Otonomy media release, the company discontinued development of OTO-313 based on data from NCT04829214 trial.
10 Nov 2022 Status changed from planning to withdrawn prior to enrolment, according to an Otonomy media release.
09 May 2022 According to an Otonomy media release, data from 700348967 and phase 2 trial (NCT04829214) are expected to support an End-of-Phase 2 meeting with the FDA and inform the design of the OTO-313 Phase 3 clinical program.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com